Lataa...
Characterization of the Synergistic Inhibition of I(K(erg)) and I(K(DR)) by Ribociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor
Ribociclib (RIB, LE011, Kisqali(®)), an orally administered inhibitor of cyclin-dependent kinase-4/6 (CDK-4/6) complex, is clinically effective for the treatment of several malignancies, including advanced breast cancer. However, information regarding the effects of RIB on membrane ion currents is l...
Tallennettuna:
| Julkaisussa: | Int J Mol Sci |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7663338/ https://ncbi.nlm.nih.gov/pubmed/33138174 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21218078 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|